NEW YORK, Feb. 13 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an updated Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc. (BNC: TSX). The full 68-page report can be found at www.crystalra.com.
Bioniche Life Sciences Inc. ("Bioniche" or "the Company") is a Canadian biopharmaceutical company that aims to improve the quality of life in both humans and animals through innovative research, technologies, and therapeutics. To develop the proprietary platform technologies that the Company uses to create human and animal therapeutic agents, Bioniche is structured in three global business units: (1) Bioniche Therapeutics (Human Health); (2) Bioniche Animal Health; and (3) Bioniche Food Safety.
The Company's most advanced Human Health product candidate is Urocidin(TM), a treatment for non-muscle-invasive bladder cancer that entered Phase III clinical development in late 2006 after the U.S. Food and Drug Administration (FDA) granted Bioniche Fast Track status. A second Phase III trial is likely to begin under the FDA's Special Protocol Assessment (SPA) and Fast Track designations after the current Phase III trial is fully enrolled and when financing is available.
Bioniche Animal Health markets over 100 products globally, developing products that enhance reproductive performance in animals and reduce the animal health industry's reliance on antibiotics. With fiscal 2008 revenues of C$17.5 million, the line of reproductive products comprises Bioniche Animal Health's largest sales category. As a whole, the business unit had fiscal 2008 revenues of C$27.7 million. A lead Animal Health product is Folltropin(R)-V, a reproductive hormone that induces superovulation in cattle and sheep.
Bioniche Food Safety develops veterinary biopharmaceuticals to improve the
safety of human food
|SOURCE Crystal Research Associates, LLC|
Copyright©2009 PR Newswire.
All rights reserved